Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.74 |
| ▸ | MMP9 | P14780 | 5/20 | 0.74 |
| ▸ | MMP8 | P22894 | 5/20 | 0.74 |
| ▸ | MMP13 | P45452 | 5/20 | 0.74 |
| ▸ | COMT | P21964 | 2/20 | 0.73 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19149751 | 0.99 | MMP2 (0.73) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL8767467 | 0.96 | MMP2 (0.81) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL8769518 | 0.95 | HPSE (0.73) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL8768340 | 0.94 | MMP2 (0.77) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL8768688 | 0.93 | MMP2 (0.65) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL8767573 | 0.92 | MAPT (0.67) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL6128131 | 0.92 | HPSE (0.65) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL14381718 | 0.91 | MMP2 (0.69) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL8768362 | 0.90 | MMP2 (0.66) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL6125964 | 0.90 | MMP2 (0.67) | MMP2MMP9MMP8MMP13COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339494-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | UNIV PARIS CITE (FR) | 2025-11-06 | — | — | US | disclosed |
| EP-4511022-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | Université Paris Cité (FR) | 2025-02-26 | — | — | EP | disclosed |
| US-20240131007-A1 | METHODS AND COMPOSITIONS FOR PICORNAVIRUS ANTI-VIRAL AGENTS | UNIVERSITY OF CONNECTICUT | 2024-04-25 | — | — | US | disclosed |
| WO-2023203162-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | UNIVERSITE PARIS CITE (FR) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203161-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | UNIVERSITE PARIS CITE (FR) | 2023-10-26 | — | — | WO | disclosed |
| EP-4265247-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | Université Paris Cité (FR) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265246-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | Université Paris Cité (FR) | 2023-10-25 | — | — | EP | disclosed |
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | UNIVERSITY OF WASHINGTON (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2017127627-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | TSPO, GBA1, NLN | MMP2 1438/4885MMP9 1226/4885MMP8 701/4885 |
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | TSPO, GBA1, NLN | MMP2 1438/4885MMP9 1226/4885MMP8 701/4885 |
| US-20250339494-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | IL2, CXCL10, IFNG | MMP2 1373/4885MMP9 1696/4885MMP8 289/4885 |
| US-20240131007-A1 | METHODS AND COMPOSITIONS FOR PICORNAVIRUS ANTI-VIRAL AGENTS | RNASEH1, HNRNPA2B1, HNRNPA1 | MMP2 1444/4885MMP9 2701/4885MMP8 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.